Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Immune Response and Safety of Both Herpes Zoster Subunit Vaccine in Healthy Adults Aged 50 Years and Older AND the Influenza Virus Vaccine in Healthy Adults Aged 18 Years and Older When Administered Sequentially or Coadministered With mRNA-1273 Booster Vaccination

Next Previous
Trial Profile

A Phase III, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Immune Response and Safety of Both Herpes Zoster Subunit Vaccine in Healthy Adults Aged 50 Years and Older AND the Influenza Virus Vaccine in Healthy Adults Aged 18 Years and Older When Administered Sequentially or Coadministered With mRNA-1273 Booster Vaccination

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elasomeran (Primary) ; GSK 137173A (Primary) ; GSK 2321138A (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 19 Jun 2023 Primary endpoint (Anti-S protein antibody concentrations expressed as GMCs in HZ/suSeq and HZ/suCoAd groups, and between-group ratios) has been met, as per results published in the Clinical Infectious Diseases.
    • 19 Jun 2023 Primary endpoint (Anti-glycoprotein E (gE) antibody concentrations expressed as Geometric Mean Concentrations (GMCs) in HZ/suSeq and HZ/suCoAd groups, and between-group ratios) has been met, as per results published in the Clinical Infectious Diseases.
    • 19 Jun 2023 Results assessing the immunogenicity and safety of COVID-19 mRNA-1273 booster vaccine in adults aged 50 years and older, published in the Clinical Infectious Diseases.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top